Maybe that's the problem with Ariad's Ridaforolimus and the "sweet" zero pace of Merck's NDA filing... Merck can't figure out a brand name and every single one they choose sounds too much like Afinitor. Merck's executives probably established a 50 person blue ribbon panel to choose a name which has to go through several different committees.
News 
Market Data 
Discover 
